Insider · CIK 0001872564

Burroughs Amy L.

Reports to the SEC for 3 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001872564

Forms 4 and 5

Insider transactions

46 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-28	TNYATenaya Therapeutics, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+120K sh	—	—	120,000
2026-05-05	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−956K sh	—	—	0
2026-05-05	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−1.25M sh	—	—	0
2026-05-05	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−300K sh	—	—	0
2026-05-05	TERNTerns Pharmaceuticals, Inc.D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−150K sh	$53.00	−$7.95M	0
2026-05-05	TERNTerns Pharmaceuticals, Inc.U Disposition from Tender	Director, Chief Executive Officer	UDisposition from Tender	−147K sh	$53.00	−$7.77M	0
2026-05-05	TERNTerns Pharmaceuticals, Inc.U Disposition from Tender	Director, Chief Executive Officer	UDisposition from Tender	−8,319 sh	$53.00	−$441K	0
2026-03-16	TERNTerns Pharmaceuticals, Inc.S Sale	Director, Chief Executive Officer	SSale	−2,770 sh	$47.30	−$131K	288,976
2026-03-16	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−14.6K sh	—	—	955,534
2026-03-16	TERNTerns Pharmaceuticals, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+14.6K sh	$4.64	+$67.7K	303,559
2026-03-16	TERNTerns Pharmaceuticals, Inc.S Sale	Director, Chief Executive Officer	SSale	−11.8K sh	$46.57	−$550K	291,746
2026-02-17	TERNTerns Pharmaceuticals, Inc.S Sale	Director, Chief Executive Officer	SSale	−4,083 sh	$39.80	−$163K	288,976
2026-02-17	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−14.6K sh	—	—	970,117
2026-02-17	TERNTerns Pharmaceuticals, Inc.S Sale	Director, Chief Executive Officer	SSale	−8,159 sh	$39.22	−$320K	293,059
2026-02-17	TERNTerns Pharmaceuticals, Inc.S Sale	Director, Chief Executive Officer	SSale	−2,341 sh	$38.07	−$89.1K	301,218
2026-02-17	TERNTerns Pharmaceuticals, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+14.6K sh	$4.64	+$67.7K	303,559
2026-01-15	TERNTerns Pharmaceuticals, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+27.1K sh	$4.64	+$126K	316,059
2026-01-15	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−14.6K sh	—	—	984,700
2026-01-15	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−27.1K sh	—	—	999,283
2026-01-15	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−27.1K sh	—	—	1,026,366
2026-01-15	TERNTerns Pharmaceuticals, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+14.6K sh	$4.64	+$67.7K	357,725
2026-01-15	TERNTerns Pharmaceuticals, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+27.1K sh	$4.64	+$126K	343,142
2026-01-15	TERNTerns Pharmaceuticals, Inc.S Sale	Director, Chief Executive Officer	SSale	−7,521 sh	$37.53	−$282K	288,976
2026-01-15	TERNTerns Pharmaceuticals, Inc.S Sale	Director, Chief Executive Officer	SSale	−61.2K sh	$37.02	−$2.27M	296,497
2026-01-14	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+300K sh	—	—	300,000
2026-01-14	TERNTerns Pharmaceuticals, Inc.A Award	Director, Chief Executive Officer	AAward	+150K sh	—	—	288,976
2026-01-05	TERNTerns Pharmaceuticals, Inc.S Sale	Director, Chief Executive Officer	SSale	−71.3K sh	$38.10	−$2.72M	138,976
2026-01-05	TERNTerns Pharmaceuticals, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+150K sh	—	—	210,315
2026-01-05	TERNTerns Pharmaceuticals, Inc. · Restricted Stock UnitM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−150K sh	—	—	0
2026-01-02	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−21.6K sh	—	—	1,053,449
2026-01-02	TERNTerns Pharmaceuticals, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+21.6K sh	$4.64	+$100K	60,315
2025-06-25	TERNTerns Pharmaceuticals, Inc.P Purchase	Director, Chief Executive Officer	PPurchase	+23.3K sh	$3.87	+$90.2K	47,083
2025-05-29	TNYATenaya Therapeutics, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+107K sh	—	—	107,400
2025-01-30	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+1.08M sh	—	—	1,075,000
2024-12-05	TERNTerns Pharmaceuticals, Inc.P Purchase	Director, Chief Executive Officer	PPurchase	+15.5K sh	$7.15	+$110K	19,099
2024-11-30	TERNTerns Pharmaceuticals, Inc.P Purchase	Director, Chief Executive Officer	PPurchase	+510 sh	$5.11	+$2,606.1	19,609
2024-10-18	TNYATenaya Therapeutics, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+34K sh	—	—	34,000
2024-03-01	TERNTerns Pharmaceuticals, Inc. · Stock Option (Right to buy)A Award	Director, Chief Executive Officer	AAward	+1.25M sh	—	—	1,250,000
2024-03-01	TERNTerns Pharmaceuticals, Inc. · Restricted Stock UnitA Award	Director, Chief Executive Officer	AAward	+150K sh	—	—	150,000
2023-06-09	TNYATenaya Therapeutics, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+14.8K sh	—	—	14,766
2023-01-03	DMACDiaMedica Therapeutics Inc.A Award	Director	AAward	+17.2K sh	$1.53	+$26.2K	73,288
2022-12-05	TNYATenaya Therapeutics, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+40K sh	—	—	40,000
2022-06-01	DMACDiaMedica Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+13.2K sh	—	—	13,222
2022-01-03	DMACDiaMedica Therapeutics Inc.A Award	Director	AAward	+11.2K sh	$3.58	+$40K	56,132
2021-08-16	DMACDiaMedica Therapeutics Inc.P Purchase	Director	PPurchase	+45K sh	$3.15	+$142K	44,950
2021-07-15	DMACDiaMedica Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+18.8K sh	—	—	18,786

Recent filings

Accepted (ET)
May 294
Burroughs Amy L.0001193125-26-249052
SEC(opens sec.gov)
May 54
Burroughs Amy L.0001872564-26-000010
SEC(opens sec.gov)
Mar 174
Burroughs Amy L.0001872564-26-000008
SEC(opens sec.gov)
Feb 184
Burroughs Amy L.0001872564-26-000006
SEC(opens sec.gov)
Jan 164
Burroughs Amy L.0001872564-26-000004
SEC(opens sec.gov)

Companies

Address

C/O TENAYA THERAPEUTICS, INC. 171 OYSTER POINT BLVD., 5TH FLOOR

SOUTH SAN FRANCISCO, CA, 94080